Novel Treatment for Brain Injury

NeuroRepair, Inc. is developing novel therapeutics for brain injury, stroke and neurodegenerative disease. The company is initially focused on treatment of both acute and chronic (long-term) stroke damage using proprietary derivatives of the peptide Transforming Growth Factor-alpha (TGFα). Preliminary experiments indicate that the regenerative properties of Transforming Growth Factor-alpha may be therapeutically effective months, or even years, after stroke or occurrence of other types of neurological injury.

The only current treatment for certain patients who have experienced a stroke is tissue plasminogen activator (tPA), a clot-dissolving agent with a therapeutic window of only a few hours. It is used to treat fewer than 5% of patients. Stroke is the leading cause of long-term disability in the United States, where there are 700,000 strokes each year and more than 4.7 million stroke survivors.